NRXP Company Profile and Key Details

NRXP has shown weak momentum, losing -1.8% over the past week and -31.45% over the past quarter, though year-to-date performance is down -19.56%. Short-term trend indicators are bullishly aligned (SMA20 2.12%, SMA50 -9.99%, SMA200 -27.72%). The stock’s 14-day RSI is 48.26 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.74% below its high and over 22.15% above its low. Average 10-day trading volume of 739.00 thousand shares is below the 3-month average of 1.28 million, indicating normal recent market interest.

NRx Pharmaceuticals, Inc. has 23.77 million shares outstanding. The public float is 13.61 million shares, elevated short interest at 3.03% of float. This equals 545.48 thousand shares. The short ratio is 2.06 days. Institutional investors hold 28.8% of the float. Insiders own 11.55%. Javitt Daniel C. holds 9.63 million shares, Hurvitz Chaim has 570.00 thousand shares and Polar Asset Management Partners Inc. has 488.04 thousand shares.

NRx Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.58. This means the shares are trading above this model’s fair value.

The latest quarter delivered EPS of -$0.04. The next quarter is forecast at $0.01. Next year's EPS is expected at $49.45. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 35 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $49.00 to $25.00. The high target offers 1156.41% upside. The low target suggests 541.03% downside. The mean target is $35.14. This offers 801.03% upside. NRx Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 18, 2026, missed forecasts by -20.0%. The prior quarter beat by -20.0%. Over the last six quarters, Apple has recorded several small beats. These include 50.0% in March 14, 2025.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) closed at $3.90 USD, losing -$0.07 (-1.76%) from the previous close of $3.97. The stock is currently mid-range between its 52-week high and low $1.62 and $5.05. With a market capitalization of about $67.41 million, NRx Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.19). Key stats such as the average daily volume over the past year has been around 1.27 million shares, volume is running light vs its 52-week average. Headquartered in Wilmington, DE, NRx Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan C. Javitt, the company employs approximately 2 people and listed since December 04, 2017. NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases.

NRx Pharmaceuticals, Inc. trades at a P/E ratio of -3.11, slightly below the S&P 500 average, with a price-to-sales ratio of 30.12 and a price-to-book ratio of -9.35 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.63, also above market averages.

Our AI price prediction model suggests that NRx Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.51%, with price expected at $4.31 by July 06, 2026, within a range of $3.87 to $4.76 3-Month Outlook: Projected fall of -55.64%, reaching $1.73 by September 18, 2026, with a range of $1.32 to $1.91. 1-Year Outlook: Projected gain of 410.0%, with price at $19.89 by June 22, 2027, within a range of $6.01 to $30.23.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) shares are down -19.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NRx Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -3.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $31.70, suggesting 712.82% upside. Our AI forecast model points to short-term strength (10.51% over two weeks), a medium-term fall (-55.64% over three months), and a longer-term gain (410.0% over one year), with expected trading ranges indicating moderate volatility.